FAP and congestive heart failure: Compared with the CHF model group, cardiomyocytes in the captopril group, UAS-H, SFAS-H, SFAS-L, GCAS, and DGSAS groups were arranged in a more orderly manner, the spacing between cells was reduced, the cell damage was improved, inflammatory cell infiltration was reduced, and cardiomyocyte damage in the captopril group and FAP-H group was significantly reduced (Figure 6).